TikkunLev Therapeutics

TikkunLev Therapeutics is on a mission to revolutionize the treatment of heart failure by targeting the underlying biology of failing heart muscle. Founded on the pioneering research of Professor Robin Shaw M.D., Ph.D., our lead program, TLT-101, is a precision therapy that targets the underlying protein trafficking defects in heart failure. Extensive preclinical data demonstrate an unprecedented efficacy and safety profile with our therapeutic approach. TLT-101 is in IND-enabling development for non-ischemic dilated cardiomyopathy (DCM), a severe and progressive disease that is a leading cause of heart failure. With cardiovascular disease remaining the leading global cause of death and 1 in 4 people expected to develop heart failure, our innovative approach aims to repair the heart and transform lives.